Biotech company Metsera, which develops weight-loss drugs and is backed by ARCH Venture Partners, said on Monday that it is ...

Gypsy-Rose Blanchard is setting the record straight when it comes to rumors circulating about her baby daughter Aurora Raina ...

Gypsy-Rose Blanchard is setting the record straight when it comes to rumors circulating about her baby daughter Aurora Raina ...

The singer shared that she was dropped by her record label for "being too fat" and confessed, "I thought I needed Ozempic to ...

Weight-loss drug developer Metsera is targeting an up to $1.78 billion valuation in its initial public offering, the ARCH Venture Partners-backed biotech company said on Monday. New York City-based ...

Patients taking Novo Nordisk’s Wegovy plus Veru’s enobosarm saw 71% lower lean mass loss than those who were takin Wegovy ...

Lean mass constituted 30.8% of total body weight lost for adults who received a GLP-1 drug during a randomized controlled ...

An ideal Mounjaro diet plan should focus on nutrient-dense foods, such as fruits, vegetables, whole grains, lean proteins, ...

Novo Nordisk - which manufactures Wegovy, Ozempic and Saxenda - misreported, under-reported or did not disclose funding it ...

Weight-loss drug developer Metsera on Monday said it was is targeting to raise as much as $292.2 million in an initial public offering.

With GLP-1-related drugs having won the race to weight loss approval, attention at many obesity-focused biopharmas has turned ...

Veru said on Monday its experimental drug, in combination with Novo Nordisk's weight-loss treatment Wegovy, helped preserve muscle in older patients with obesity, meeting the main goal of a mid-stage ...